Cart
sales@molnova.com
Sibrotuzumab
CAS No. 216669-97-5
Sibrotuzumab( —— )
Catalog No. M36723 CAS No. 216669-97-5
Sibrotuzumab (BIBH 1) is a humanized IgG1 monoclonal antibody targeting Fibroblast Activating Protein (FAP) and is used in the study of colorectal cancer and non-small cell lung cancer.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 476 | Get Quote |
|
| 5MG | 630 | Get Quote |
|
| 10MG | 1007 | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameSibrotuzumab
-
NoteResearch use only, not for human use.
-
Brief DescriptionSibrotuzumab (BIBH 1) is a humanized IgG1 monoclonal antibody targeting Fibroblast Activating Protein (FAP) and is used in the study of colorectal cancer and non-small cell lung cancer.
-
DescriptionSibrotuzumab (BIBH 1) is a humanized IgG1 monoclonal antibody targets fibroblast activation protein (FAP). Sibrotuzumab can be used for the research of colorectal cancer and non-small cell lung cancer (NSCLC).
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayOthers
-
TargetOther Targets
-
RecptorOthers
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number216669-97-5
-
Formula Weight
-
Molecular Formula——
-
Purity>98% (HPLC)
-
Solubility——
-
SMILES——
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Scott AM, et al. A Phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res. 2003 May;9(5):1639-47.?
molnova catalog
related products
-
Cirsiliol
Cirsiliol is a selective inhibitor of 5-lipoxygenase and a competitive low-affinity ligand of benzodiazepine receptors.
-
Apigenin 5-O-beta-D-...
Apigenin 5-O-beta-D-glucopyranoside has inhibitory activity against the enzyme yeast a-glucosidase, withthe IC50 value of 287.12 muM.
-
β-CGRP, human TFA (1...
β-CGRP,human tissue is one of the calcitonin peptide, through complex behavior of calcitonin receptor like receptor (CRLR) - and receptor activity - modifying proteins (increased), and 1 and 300 - nM CRLR IC50s/RAMP1 and CRLR/RAMP2 cells.
